No supplier or customer ties in VOR's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Nothing on the wire mentions VOR yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How VOR has moved on past release days vs its typical ±5.0% day, and how often it closed up. Computed from daily closes — not a forecast.